Measuring rates of return for disease management programmes is controversial and challenging. There are significant costs associated with the disease management programme design, evaluation and maintenance. The literature shows that a disease management programme is not a guarantee of cost savings, but in addition to community health improvements and improved clinical outcomes, desired cost savings can be realised if the programme is designed correctly.